Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | BRD2 | P25440 | 2/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217325 | 0.98 | PNP (0.49) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5054173 | 0.87 | PNP (0.54) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6233163 | 0.84 | PNP (0.58) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5428518 | 0.83 | GAA (0.40) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27277482 | 0.83 | ALDH1A1 (0.52) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL24499702 | 0.83 | PNP (0.48) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9885862 | 0.83 | PNP (0.45) | PNPSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL27586845 | 0.83 | PNP (0.53) | PNPGDASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL27573642 | 0.83 | PNP (0.50) | PNPGDASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL9386892 | 0.82 | PNP (0.47) | PNPGDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946353-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-02-09 | — | — | EP | claimed |
| WO-2020193567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2020-10-01 | — | — | WO | claimed |
| US-5700369-A | Process for adsorboaggregational flotation of Carlin type natural gold ore dressing | GUANGZHOU INSTITUTE OF GEOCHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 1997-12-23 | — | — | US | claimed |
| CN-122029936-A | Light-emitting element, display device, and method for manufacturing light-emitting element | 夏普显示科技株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-115745998-B | Method for synthesizing gouache mushroom and analogue thereof by photocatalysis | 新乡学院 | 2024-10-22 | — | — | CN | disclosed |
| EP-3946353-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| EP-3765014-A1 | METHODS AND COMPOSITIONS OF INHIBITING CSF1R FOR TREATING ALLERGIC INFLAMMATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2019204604-A1 | METHODS AND COMPOSITIONS OF INHIBITING CSF1R FOR TREATING ALLERGIC INFLAMMATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | NOVOMER, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-1995007082-A1 | A COMBINATION TABLET COMPRISING ACETYLSALICYLIC ACID AND A PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 1995-03-16 | — | — | WO | disclosed |
| EP-0528951-A4 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0528951-A1 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | CELLTECH LIMITED (GB) | 1993-03-03 | — | — | EP | disclosed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | disclosed |
| WO-1992007566-A2 | ANTIFUNGAL ACTIVITY OF AND PREVENTION OF DRUG INDUCED NEPHROTOXICITY BY METHYLXANTHINE ANALOGUES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991016927-A1 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | CELLTECH LIMITED (GB) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | PNP 1202/4885ADORA2A 368/4885PDE4A 574/4885 |
| US-20180179242-A1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | PPOX, COASY, SOD1 | PNP 950/4885ADORA2A 4627/4885PDE4A 4210/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | PNP 348/4885ADORA2A 900/4885PDE4A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.